Skip to main content
. 2018 Sep 10;54(1):87–95. doi: 10.1007/s00535-018-1503-x

Table 3.

Rates of SVR12 by subgroup

Sofosbuvir–velpatasvir 12 weeks N = 51 Sofosbuvir–velpatasvir plus ribavirin 12 weeks N = 51
Overall SVR12 47/51 (92) 47/51 (92)
 Genotype
  1a 0/1 (0)
  1b 39/40 (98) 35/39 (90)
  2 8/9 (89) 12/12 (100)a
  3 0/1 (0)
 Baseline CPT class
  A 1/1 (100) 2/2 (100)
  B 38/40 (95) 38/39 (97)
  C 8/10 (80) 7/10 (70)

aIncludes 1 patient who was initially categorized as missing HCV genotype, and subsequently determined to have genotype 2a by BLAST analysis